Orbital ATK, Inc. OA
134.50 0.00 (+0.00%)
At closeJun 28, 2019, 6:07 PM EDT
134.47 Day range 134.51
52-week range unavailable
- YTD
- -100.00%
- 1 year
- -100.00%
News
gurufocus.com Omnicom Advertising Announces Leadership Transition Omnicom Advertising Announces Leadership Transition PR Newswire NEW YORK, Sept. 9, 2026
gurufocus.com The Hackett Group® Announces Winners of the 2026 Hackett Innovation Awards [url="]The Hackett Group, Inc. (NASDAQ: HCKT)[/url], an ROI-led AI transformation firm, today announced the winners of its annual [url="]Hackett Innovation Awa
gurufocus.com Eli Lilly's Retatrutide Shows Promising Results in Obesity and Osteoarthritis Trial Eli Lilly (LLY) is seeing a positive market response after announcing successful topline results from its Phase 3 TRIUMPH-4 clinical trial. The trial evaluated
businesswire.com Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the…
businesswire.com Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Lenivia approval by Health Canada marks major milestone in the company's continued innovation for canine OA pain.
businesswire.com Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection.
businesswire.com Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain…
businesswire.com Pfizer And Lilly Announce Positive Top-Line Results From Phase 3
Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain NEW YORK, & INDIANAPOLIS--(BUSINESS WIRE)--Pfizer Inc.(NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating…
benzinga.com Play Offense With This Defense ETF 
businesswire.com Orbital ATK to Announce Second Quarter 2017 Financial Results on
August 3 DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, today announced that it will release its second quarter 2017 financial results prior…
businesswire.com Orbital ATK to Announce First Quarter 2017 Financial Results
on May 11 DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, today announced that it will release its first quarter 2017 financial results prior…
benzinga.com Earnings Scheduled For March 8, 2017 
businesswire.com Orbital ATK to Announce Fourth Quarter and Full Year 2016 Financial
Results on March 8 DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, today announced that it will release its fourth quarter and full year 2016 financial…
businesswire.com Orbital ATK to Conduct Conference Call with Financial Analysts on
November 8 DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, announced today that it will conduct a conference call with financial analysts to…
businesswire.com Orbital ATK Announces Preliminary Second Quarter 2016 Financial
Results DULLES, VA.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE:OA), a global leader in aerospace and defense technologies, today announced preliminary unaudited financial results for the second quarter ended…
businesswire.com Orbital ATK Announces First Quarter 2016 Financial Results DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE:OA), a global leader in aerospace and defense technologies, today announced financial results for the first calendar quarter ended April 3, 2016.…
businesswire.com Orbital ATK to Announce Fourth Quarter and Full Calendar Year 2015
Financial Results on February 29 DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, today announced that it will release its financial results for the fourth quarter…
businesswire.com Orbital ATK Announces Third Calendar Quarter 2015 Financial Results DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE:OA), a global leader in aerospace and defense technologies, today announced both GAAP and adjusted financial results for the third calendar…
businesswire.com Orbital ATK Announces Second Calendar Quarter 2015 Financial Results DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE:OA), a global leader in aerospace and defense technologies, today announced both GAAP and adjusted financial results for the second calendar…
businesswire.com CORRECTING and REPLACING Orbital ATK Announces Financial Results for
Quarter Ended March 31, 2015 DULLES, Va.--(BUSINESS WIRE)--Orbital ATK will pay its quarterly dividend for shareholders of record as of June 8 on June 25, not June 28 stated in today’s press release. The correction has been made…
businesswire.com Orbital ATK to Hold Conference Call with Investors and Analysts on
February 19 DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, today announced that it will hold a conference call with investors and analysts on…